Weighted Average Number of Shares Outstanding, Diluted of Royalty Pharma plc from 30 Jun 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Royalty Pharma plc quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2020 to 31 Dec 2025.
  • Royalty Pharma plc Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 564,455,000, a 5% decline year-over-year.
  • Royalty Pharma plc annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 564,455,000, a 5% decline from 2024.
  • Royalty Pharma plc annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 594,108,000, a 1.5% decline from 2023.
  • Royalty Pharma plc annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 602,900,000, a 38% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Royalty Pharma plc Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 564,455,000 -29,653,000 -5% 01 Oct 2025 31 Dec 2025 10-K 11 Feb 2026 2025 FY
Q3 2025 559,611,000 -33,115,000 -5.6% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 562,298,000 -34,614,000 -5.8% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 578,102,000 -19,377,000 -3.2% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 594,108,000 -8,792,000 -1.5% 01 Oct 2024 31 Dec 2024 10-K 11 Feb 2026 2025 FY
Q3 2024 592,726,000 -8,412,000 -1.4% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 596,912,000 -8,948,000 -1.5% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 597,479,000 -9,772,000 -1.6% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 602,900,000 +164,928,000 +38% 01 Oct 2023 31 Dec 2023 10-K 11 Feb 2026 2025 FY
Q3 2023 601,138,000 -6,088,000 -1% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 605,860,000 -1,354,000 -0.22% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 607,251,000 +50,000 +0.01% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 437,972,000 +23,170,000 +5.6% 01 Oct 2022 31 Dec 2022 10-K 12 Feb 2025 2024 FY
Q3 2022 607,226,000 +52,000 +0.01% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 607,214,000 +51,000 +0.01% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 607,201,000 +53,000 +0.01% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 414,802,000 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 607,174,000 +237,172,000 +64% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 607,163,000 +253,183,000 +72% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 607,148,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 370,002,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 353,980,000 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2

Royalty Pharma plc Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 564,455,000 -29,653,000 -5% 01 Jan 2025 31 Dec 2025 10-K 11 Feb 2026 2025 FY
2024 594,108,000 -8,792,000 -1.5% 01 Jan 2024 31 Dec 2024 10-K 11 Feb 2026 2025 FY
2023 602,900,000 +164,928,000 +38% 01 Jan 2023 31 Dec 2023 10-K 11 Feb 2026 2025 FY
2022 437,972,000 +23,170,000 +5.6% 01 Jan 2022 31 Dec 2022 10-K 12 Feb 2025 2024 FY
2021 414,802,000 +39,347,000 +10% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 375,455,000 01 Jan 2020 31 Dec 2020 10-K 15 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.